Special Issue

Unveiling the Genetic Architecture of Complex and Common Diseases

Message from the Guest Editor

This Special Issue aims to explore the genetic architecture underlying complex and common diseases by integrating advanced genomic technologies. bioinformatics approaches, and large-scale population studies. By identifying genetic variants, interactions, and molecular pathways associated with these diseases, the research seeks to enhance our understanding of disease etiology, improve risk prediction models, and contribute to the development of personalized medicine strategies. The scope of the Special Issue includes genetic variants and disease susceptibility, polygenic risk scores, gene-environment interactions, multi-omics approaches, computational and statistical models, and clinical and translational impact. This Special Issue will provide valuable insights into the genetic basis of multifactorial diseases such as cardiovascular disorders, diabetes, neurodegenerative diseases, and autoimmune conditions, ultimately advancing biomedical science and healthcare solutions.

Guest Editor

Dr. Mahmut Cerkez Ergoren

Medical Genetic Diagnostic Laboratory, Near East University Hospital, Near East University, Nicosia 99138, Cyprus

Deadline for manuscript submissions

30 September 2025



an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/232961

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).